Tonix Pharmaceuticals (TNXP), Tonmya Prescriptions Surpass 4,200 Cases……Leveraging FDA-Approved Drug Efficacy to Achieve "Dual-Track Growth" in Sales and Clinical Results

Tonix Pharmaceuticals (TNXP) is accelerating its business expansion through commercialization achievements and clinical data releases. As sales figures and clinical results for the fibromyalgia treatment drug “Tonmya” are recently announced one after another, investor attention continues to focus.

Tonix Pharmaceuticals stated that since Tonmya’s launch in November 2025, approximately 1,500 prescribing physicians and 2,500 patients have used the medication as of the end of February 2026. The total prescriptions amount to about 4,200. The company’s net product sales for 2025 reached $13.1 million, and as of the end of that year, cash holdings were $206 million. Additionally, the company raised extra funds through a $20 million direct public offering, enhancing liquidity.

Tonmya is a sublingual fibromyalgia treatment approved by the U.S. Food and Drug Administration (FDA) in August 2025. Its advantage lies in faster absorption and higher bioavailability compared to traditional oral medications. Phase 3 clinical trial results showed pain relief within the first two days of treatment, with statistically significant improvements on the primary endpoint at week 14. The company emphasizes, “Rapid onset of efficacy and good tolerability are key differentiators from existing treatments.”

Academic conference presentations are ongoing. Tonix Pharmaceuticals has released clinical data for Tonmya at the American Academy of Pain Medicine (AAPM) and the International Fibromyalgia Conference, boosting credibility. Notably, in the RESILIENT clinical trial, not only was pain reduced, but positive effects on sleep improvement and fatigue relief, overall enhancing patients’ quality of life, were also highlighted.

Meanwhile, the company is accelerating the expansion of its immuno-oncology and central nervous system (CNS) R&D pipelines. It plans to present preclinical immuno-oncology combination data at the American Association for Cancer Research (AACR) annual meeting in April 2026, including findings related to gastric cancer tumor biology, antibody therapies, and pharmacokinetics.

Additionally, Tonix has uplisted to the Nasdaq Global Select Market, strengthening its corporate credibility and accessibility to institutional investors. The company states that this listing is a result of meeting financial requirements and corporate governance standards, which is expected to positively impact future liquidity and market recognition.

Industry analysts believe that Tonix Pharmaceuticals has entered the commercialization early stage, with its enterprise value depending on the expansion of Tonmya prescriptions and progress in clinical pipelines. A biotech investment expert commented, “Currently, the company is in a phase where both commercialization sales and clinical progress are driving growth,” adding, “In the short term, prescription growth rate is key; in the medium to long term, the success or failure of CNS and immune disease pipelines’ clinical trials is the core variable.”

Tonix also plans to introduce its main R&D pipelines and commercialization strategies at BIO-Europe Spring 2026 in Lisbon, Portugal in March. The market is watching whether this presentation can make the company’s growth strategy and global collaboration prospects more concrete.